1 Day
Source:
وكالة الانباء الاردنية
Source: وكالة الانباء الاردنية
1 Dayوكالة الانباء الاردنية
Source: وكالة الانباء الاردنية
1 DayReady to play
Ready to play
Merk and Moderna announced positive results from the final phase of trials for an experimental vaccine based on mRNA technology to treat advanced melanoma skin cancer. The treatment, which is used in conjunction with the immunotherapy drug Keytruda, showed a statistically significant improvement in the relapse-free survival rate among patients who had previous surgeries, compared to treatment with Keytruda alone. The new vaccine is designed to develop a personalized therapy based on each patient's tumor mutations, aiming to train the immune system to recognize and attack cancer cells. This marks an unprecedented advancement in cancer treatment using mRNA technology.
Notice: This Is an AI-Generated Summary
Comments (0)